drugset / Trial / NCT00334581

Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria

NCT00334581

Phase 4 Completed 192 enrolled Sanofi Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Primary objective: * To determine if irbesartan 300mg is better than 150mg in protecting the kidneys in hypertensive patients with diabetes and microalbuminuria. Secondary objectives: * To determine how well irbesartan 300mg is tolerated versus 150mg * To determine the percentage of patients reaching the blood pressure target of 130/80 mmHg

Timeline

Start
2006-05
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Irbesartan Small molecule 150 mg
Subject Irbesartan Small molecule 300 mg

Indications